RxDoctor Payments Data

John Wilson, MD

Psychiatry · Lynchburg, VANPI 1164423836

Payments from drug & device makers

$1,749in general payments, 2019–2025

Across 97 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$298
  • Neurocrine Biosciences, Inc.$272
  • AbbVie$219
  • Alkermes, Inc.$172
  • Otsuka America Pharmaceutical, Inc.$125
  • Sunovion Pharmaceuticals Inc.$111
  • plus $552 from 10 others

What the payments were for

  • Food & beverage$1,70297%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,749 in reported general payments places this provider in the 80th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$6,295
Medicare patients
39
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole49$137,780
VraylarCariprazine Hcl61$91,518
IngrezzaValbenazine Tosylate11$85,587
AristadaAripiprazole Lauroxil23$68,689
Invega SustennaPaliperidone Palmitate30$48,701
CaplytaLumateperone Tosylate20$34,518
RexultiBrexpiprazole12$26,036
Aripiprazole101$9,086
Lisdexamfetamine Dimesylate12$6,045
Olanzapine56$4,864
Clozapine85$4,823
Lurasidone Hcl19$2,757
Buspirone Hcl184$2,571
Quetiapine Fumarate ErQuetiapine Fumarate36$2,376
Quetiapine Fumarate106$1,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$125$163,81661 claims
AbbVieVraylar$219$91,51861 claims
Neurocrine Biosciences, Inc.Ingrezza$272$85,58711 claims
Alkermes, Inc.Aristada$172$68,68923 claims
Johnson & JohnsonInvega Sustenna$298$48,70130 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$110$34,51820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →